AMP ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 11 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04068246 (ClinicalTrials.gov) | August 1, 2019 | 21/8/2019 | The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients | The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. | Rheumatoid Arthritis | Drug: Metformin;Drug: Placebo | Sadat City University | NULL | Completed | 18 Years | N/A | All | 120 | Phase 1/Phase 2 | Egypt |
| 2 | NCT02277574 (ClinicalTrials.gov) | June 2014 | 23/7/2014 | Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis | A Randomized, Multi-Dose, Placebo-Controlled, Study of the Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: AMP-110;Other: Placebo | MedImmune LLC | Daiichi Sankyo Co., Ltd. | Completed | 18 Years | 75 Years | Both | 29 | Phase 1 | United States |
| 3 | NCT01851278 (ClinicalTrials.gov) | April 2013 | 12/4/2013 | Effectiveness Intraarticular Corticosteroid | Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose | Rheumatoid Arthritis | Drug: Triamcinolone hexacetonide | Federal University of São Paulo | Fundação de Amparo à Pesquisa do Estado de São Paulo | Recruiting | 18 Years | 65 Years | Both | 60 | N/A | Brazil |
| 4 | NCT01878123 (ClinicalTrials.gov) | April 2013 | 22/5/2013 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis | A Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: AMP-110;Other: Placebo | MedImmune LLC | Daiichi Sankyo Co., Ltd.;Daiichi Sankyo Co., Ltd. | Completed | 18 Years | 75 Years | Both | 26 | Phase 1 | United States |
| 5 | JPRN-UMIN000008812 | 2012/10/01 | 01/10/2012 | Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR) | Rheumatoid arthritis | tocilizumab monotherapy | Department of Rheumatology & Clinical ImmunologySaitama Medical Center, Saitama Medical Universitity | NULL | Complete: follow-up complete | 16years-old | 80years-old | Male and Female | 40 | Not selected | Japan | |
| 6 | JPRN-UMIN000007019 | 2012/02/01 | 01/02/2012 | Efficacy and safety of tocilizumab mono-therapy in patients with adult-onset Still's disease | Rheumatoid arthritis | tocilizumab monotherapy | Department of Rheumatology & Clinical Immunology,Saitama Medical Center, Saitama Medical Universitity | NULL | Complete: follow-up complete | 16years-old | 70years-old | Male and Female | 40 | Not selected | Japan | |
| 7 | JPRN-UMIN000005773 | 2011/06/01 | 14/06/2011 | Magnetic resonance image analysis for quantification of knee articular cartilage verified response to etanercept(ETN) in subjects with active rheumatoid arthritis | rheumatoid arthritis | ETN+MTX MTX | 22nd Century Medical & Research Center, the University of Tokyo | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 20 | Not selected | Japan | |
| 8 | NCT01151644 (ClinicalTrials.gov) | April 2010 | 25/6/2010 | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases | Rheumatoid Arthritis;Spondyloarthritis;Systemic Lupus Erythematosus (SLE);Dermatomyositis (DM);DMixed Connective Tissue Disease;Systemic Vasculitis;Systemic Sclerosis (SSc);Sjögren's Syndrome;Antiphospholipid Syndrome;Juvenile Idiopathic Arthritis;Juvenile SLE;Juvenile DM | Biological: Anti-pandemic H1N1 influenza vaccine | University of Sao Paulo | Fundação de Amparo à Pesquisa do Estado de São Paulo | Active, not recruiting | N/A | N/A | Both | 5000 | Phase 4 | Brazil |
| 9 | JPRN-UMIN000001240 | 2008/07/01 | 10/07/2008 | The efficacy of tocilizumab to patients with rheumatoid arthritis refractory to anti-TNF agents: the open trial | rheumatoid arthritis | Tocilizumab (8 mg/kg of body weight) is to be infused every 4 weeks for 3 years | Division of Rheumatology & Clinical Immunology, Jichi Medical University | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan | |
| 10 | NCT00239382 (ClinicalTrials.gov) | July 1, 2004 | 13/10/2005 | A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis | A Randomized, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 15 mg IM Ampoules Once Daily and Meloxicam 15 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With RA. | Arthritis, Rheumatoid | Drug: Meloxicam ampoule;Drug: Meloxicam tablet | Boehringer Ingelheim | NULL | Completed | 18 Years | N/A | All | 150 | Phase 3 | China |
| 11 | NCT02184052 (ClinicalTrials.gov) | July 2003 | 3/7/2014 | Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions | Meloxicam (MOBIC®) Ampoule Post Marketing Surveillance Study | Arthritis, Rheumatoid | Drug: Meloxicam | Boehringer Ingelheim | NULL | Completed | N/A | N/A | Both | 121 | N/A | NULL |